USPTO Deadlines
Application History
14 eventsDate | Code | Type | Description | Documents |
---|---|---|---|---|
Mar 14, 2025 | OPNX | P | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | Loading... |
Feb 27, 2025 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
Feb 27, 2025 | OPNR | P | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | Loading... |
Oct 10, 2024 | MAB2 | O | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | Loading... |
Oct 10, 2024 | ABN2 | O | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | Loading... |
Apr 24, 2024 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
Mar 29, 2024 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
Mar 28, 2024 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
Mar 10, 2024 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
Mar 9, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
Mar 6, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Oct 3, 2023 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
Sep 29, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
Sep 28, 2023 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 005
Viral systems, gene therapy systems, nucleic acid delivery systems, namely, viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors or nucleic acid delivery vectors for medical purposes; pharmaceutical products; biological preparations for use in medical and clinical gene therapy, nucleic acid-based therapy and cell therapy; clinical medical reagents for use in nucleic acid-based therapy, gene therapy, cell therapy, gene diagnosis and gene testing; pharmaceutical preparations, vaccines, prophylaxis products and other pharmaceutical products for use in nucleic acid-based therapy, gene therapy and cell therapy
Class 042
Research, product development and consultancy in the field of biotechnology, biologics, medical science, chemistry and biochemistry; research and product development in the field of pharmaceutics
Class 044
Gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders, inherited disorders, genetic disorders and single gene disorders; consultancy in the field of pharmaceutics
Additional Information
Pseudo Mark
SORT TAG
Classification
International Classes
005
042
044